Your browser doesn't support javascript.
loading
Efficacy of Transcranial Direct-Current Stimulation in Catatonia: A Review and Case Series.
Haroche, Alexandre; Giraud, Nolwenn; Vinckier, Fabien; Amad, Ali; Rogers, Jonathan; Moyal, Mylène; Canivet, Laetitia; Berkovitch, Lucie; Gaillard, Raphaël; Attali, David; Plaze, Marion.
Afiliação
  • Haroche A; GHU PARIS Psychiatrie and Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France.
  • Giraud N; Université de Paris, Paris, France.
  • Vinckier F; GHU PARIS Psychiatrie and Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France.
  • Amad A; Université de Paris, Paris, France.
  • Rogers J; GHU PARIS Psychiatrie and Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France.
  • Moyal M; Université de Paris, Paris, France.
  • Canivet L; Department of Neuroimaging, King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.
  • Berkovitch L; Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, Lille, France.
  • Gaillard R; Division of Psychiatry, University College London, London, United Kingdom.
  • Attali D; South London and Maudsley National Health Service (NHS) Foundation Trust, London, United Kingdom.
  • Plaze M; GHU PARIS Psychiatrie and Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France.
Front Psychiatry ; 13: 876834, 2022.
Article em En | MEDLINE | ID: mdl-35573356
Catatonia is a severe neuropsychiatric syndrome, usually treated by benzodiazepines and electroconvulsive therapy. However, therapeutic alternatives are limited, which is particularly critical in situations of treatment resistance or when electroconvulsive therapy is not available. Transcranial direct-current stimulation (tDCS) is a promising non-invasive neuromodulatory technique that has shown efficacy in other psychiatric conditions. We present the largest case series of tDCS use in catatonia, consisting of eight patients in whom tDCS targeting the left dorsolateral prefrontal cortex and temporoparietal junction was employed. We used a General Linear Mixed Model to isolate the effect of tDCS from other confounding factors such as time (spontaneous evolution) or co-prescriptions. The results indicate that tDCS, in addition to symptomatic pharmacotherapies such as lorazepam, seems to effectively reduce catatonic symptoms. These results corroborate a synthesis of five previous case reports of catatonia treated by tDCS in the literature. However, the specific efficacy of tDCS in catatonia remains to be demonstrated in a randomized controlled trial. The development of therapeutic alternatives in catatonia is of paramount importance.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article